{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008683","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.995841+00:00","generated_at":"2026-06-15T08:49:47.704762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kala Pharma Q1 net loss $14.5M; KPI-012 CHASE Phase 2b enrolling with topline data Q1 2024","bullets":["Q1 2023 net loss $14.5M ($6.99/share) vs $32.9M ($22.18/share) in Q1 2022; no product revenue post-Alcon sale.","Cash and equivalents $63.6M at March 31, 2023; plus $15M CIRM grant awarded April 2023 extends runway into Q1 2025.","KPI-012 for PCED received FDA Fast Track designation; CHASE Phase 2b primary enrollment ongoing; topline data targeted Q1 2024.","Appointed Dr. Francis Mah as Chief Medical Advisor in March 2023 to support clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008683","json":"https://secwatch.observer/filing/0001558370-23-008683.json","markdown":"https://secwatch.observer/filing/0001558370-23-008683.md","text":"https://secwatch.observer/filing/0001558370-23-008683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/0001558370-23-008683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/kala-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:49:47.704762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0cb88dd9d4e88f4a38d551d219479d30b766f12","claim":"KALA BIO, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 9, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2023 and provided a general business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/0001558370-23-008683-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}